# Diabetes Research Hub — Monitor Report

**Run date:** 2026-04-30
**Run type:** Automated scheduled review (read-only)
**Reporting window:** Day-over-day (2026-04-29 → 2026-04-30) and Week-over-week (2026-04-23 → 2026-04-30)

---

## File System Status

| File | Last Modified | Age | Status |
|------|---------------|-----|--------|
| `hub_monitor_report.md` | 2026-04-30 | 0d | OK |
| `clinical_trials_latest.json` | 2026-04-30 | 0d | OK |
| `clinical_trials_summary.md` | 2026-04-30 | 0d | OK |
| `pubmed_recent_latest.json` | 2026-04-30 | 0d | OK |
| `pubmed_recent_summary.md` | 2026-04-30 | 0d | OK |
| `literature_gap_report.md` | 2026-04-29 | 1d | OK |
| `literature_gap_data.json` | 2026-04-20 | 10d | OK (within 14d) |

**Hub monitor flags:** 506 historical result files >14d old (expected — these are dated snapshots, not stale outputs). Nightly snapshots are current.

**File system delta (24h, from `hub_monitor_report.md`):**
- 3 new files: today's clinical trials & PubMed snapshots, and yesterday's monitor report.
- 38 modified files (mostly Dashboards/* HTML rebuilt yesterday and today's auto-refreshed data files).
- 0 removed files.
- 771 total files tracked.

---

## Clinical Trial Changes

**Corpus:** 776 unique trials. Status distribution: 263 RECRUITING, 130 NOT_YET_RECRUITING, 110 ACTIVE_NOT_RECRUITING, 6 ENROLLING_BY_INVITATION, 267 COMPLETED. Phase 3 = 117 trials.

### Day-over-day (2026-04-29 → 2026-04-30)
- **New trials:** 1
- **Status changes:** 1
  - `NCT07422831`: NOT_YET_RECRUITING → ENROLLING_BY_INVITATION — *T2D Intermittent Nonprescription Sensors for Informed Glucose Health Tracking* (Univ. of Colorado, Denver).
- **New results posted:** 0

### Week-over-week (2026-04-23 → 2026-04-30)
- **New trials added to corpus:** 8 (including the day-over-day addition).
- **Removed:** 1.
- **Status changes:** 3.
  - `NCT07422831` (above).
  - `NCT06993792`: RECRUITING → ACTIVE_NOT_RECRUITING — *Master Protocol for Orforglipron (LY3502970) in Obesity/Overweight ± T2D* (Eli Lilly). Worth flagging — this is the orforglipron program.
  - `NCT07400588`: RECRUITING → ACTIVE_NOT_RECRUITING — *Aleniglipron Phase 2 in T2DM* (Gasherbrum Bio).
- **Newly posted results in week:** 0.
- **Recently completed with results posted (last 7d, all phases):** 3.
  - `NCT05649137` (2026-04-27, Phase 3, Novo Nordisk) — *Semaglutide for excess weight + T2D weight loss* — **High-priority review item.**
  - `NCT05734989` (2026-04-24, NA, Duke) — *Screening/Therapy for Hispanic/Latinx at risk for CKD.*
  - `NCT04831697` (2026-04-28, NA, Med College Wisconsin) — *Diabetes outcomes in older African American women w/ caregiving burden.*

### Key Phase 3 RECRUITING trials (selection)
| NCT | Sponsor | Title | Notes |
|-----|---------|-------|-------|
| NCT04786262 | Vertex Pharmaceuticals | VX-880 in T1D | Stem-cell-derived islet flagship; tracking. |
| NCT06832410 | Vertex Pharmaceuticals | VX-880 in T1D + kidney transplant | Companion arm to NCT04786262. |
| NCT07222332 | Eli Lilly | Baricitinib in newly-dx T1D children/adults | Tier 1 — JAK inhibitor for beta cell preservation. |
| NCT07088068 | Sanofi | Teplizumab vs placebo (1–25y, stage 2 T1D) | Tier 1 — supports new pediatric label expansion. |
| NCT07076199 | Novo Nordisk | Insulin icodec weekly vs daily | Key icodec data point. |
| NCT06217302 | A. Doria (JDRF) | Sotagliflozin to slow DKD in T1D | DKD progression endpoint. |

---

## PubMed Highlights

**Corpus:** 152 unique papers across 16 alert domains, 30-day lookback. 36 new papers and 39 dropped papers in the last 24h. 101 new and 93 dropped in the last 7 days.

### Cross-domain papers (highest priority, from latest snapshot)
8 cross-domain papers in the current window — all 8 are also new this week:

| PMID | Title | Domains | Journal/Date |
|------|-------|---------|--------------|
| 42050914 | Emerging therapies for T1D: Immunotherapy and gene editing advances | T1D Stem Cell Cure, T1D Immunotherapy, Gene Therapy, **teplizumab** | J Int Med Research / 2026-Apr |
| 42051156 | Considerations for clinical use of teplizumab in stage 2 T1D — BSPED Consensus Statement | T1D Immunotherapy, **teplizumab** | Diabetic Medicine / 2026-Apr-29 |
| 42023429 | Gene Therapy and Gene Editing in T1D: CRISPR β-Cell Replacement and Treg Approaches | T1D Immunotherapy, Gene Therapy | Diabetes Obes Metab / 2026-Apr-23 |
| 42032109 | Cell-specific DNA methylation in human α/β cells regulates gene expression in T2D | Gene Therapy, Epigenetics | Nature Metabolism / 2026-Apr |
| 42056522 | GLP-1R/GIPR/PPARα/γ/δ quintuple agonism corrects obesity and diabetes (mice) | T2D GLP-1 New, GLP-1 Pharmacogenomics | **Nature** / 2026-Apr-29 |
| 42051729 | ML prediction model for postoperative complications in chronic disease patients | AI/ML, Multi-Omics | Frontiers in Medicine / 2026 |
| 42046753 | Active breaks vs sitting: glucose & vascular function in T1D adults | T1D Immunotherapy*, Closed Loop AP | BMJ Open Sport Exerc Med / 2026 |
| 41297910 | Engineered nutrient-stimulated hormonal multi-agonists for obesity/metabolic disease | **orforglipron**, **retatrutide**, **CagriSema** | Clin Mol Hepatol / 2026-Apr |

\*The T1D Immunotherapy match for 42046753 looks like a keyword artifact (no immunotherapy intervention in the abstract). Worth flagging for de-tagging on the next gap-analysis pass.

### Key therapy mentions (rolling 30 days)
| Therapy | Papers in window | Δ vs week ago |
|---------|------------------|---------------|
| zimislecel | 0 | 0 |
| orforglipron | 5 | +1 |
| retatrutide | 5 | +2 |
| CagriSema | 1 | +1 |
| baricitinib | 2 | +1 |
| teplizumab | 5 | +1 |
| icodec | 2 | +2 |
| dapagliflozin | 5 | (steady) |

Notable: The **Nature** quintuple-agonist paper (42056522) and the multi-agonist review (41297910) both arrived this week — meaningful for the GLP-1 / next-gen agonist tracking line.

### Domain volume notes
- Epigenetics: 8 → 10 (+2). Driven by the Nature Metabolism α/β-cell methylation paper plus follow-ons.
- Key Therapy: icodec moved from 0 → 2 — first appearances since the previous snapshot.
- Drug Repurposing: 4 → 3 (−1) and LADA New Research: 5 → 4 (−1) — minor rolls out of window, no concern.

---

## Gap Analysis Summary

Source: `literature_gap_report.md` (generated 2026-04-29; underlying data 2026-04-20). Validation level: BRONZE (single-source bibliometric; needs expert confirmation).

### Top 5 under-researched intersections (Gap Score 100, joint pubs ≤ 1)

1. **Beta Cell Regen × Health Equity** (gap 100, 0 joint) — equity analysis of emerging cell therapies absent.
2. **Insulin Resistance × Islet Transplant** (gap 100, 1 joint) — IR in transplant recipients is barely studied.
3. **Islet Transplant × Drug Repurposing** (gap 100, 0 joint) — computational repurposing not applied to islet protection.
4. **Islet Transplant × Health Equity** (gap 100, 0 joint) — access equity for limited-center procedures unstudied.
5. **Gene Therapy × LADA** (gap 100, 0 joint) — autoimmune mechanism makes LADA a candidate, no crossover work.

### Alignment with Tier 1 contribution areas (per RESEARCH_DOCTRINE.md)
- **Drug Repurposing × Islet Transplant** (#3) and **Drug Repurposing × LADA** (#13 in extended list) align directly with the existing Drug Repurposing Screen pipeline (Dashboards/Drug_Repurposing_Screen.html, last refreshed 2026-04-29).
- **Health Equity ×** anything (Beta Cell Regen, Islet Transplant, Treg/CAR-T, Glucokinase, Drug Repurposing, LADA — six of the top 15) is a recurring Tier 1 theme; all candidates for synthesis briefs.
- **Gene Therapy × LADA** is novel and fits the LADA-deepdive line of work that Dashboards/Immunomod_LADA.html and LADA_Natural_History.html already cover.

---

## Breaking News (last 7 days)

Two genuinely significant items confirmed via web search; both align with corpus signals already detected above.

1. **FDA approval — Tzield (teplizumab-mzwv) pediatric label expansion** (Apr 22, 2026, Sanofi). Indication now extends from ≥8 years to as young as **1 year of age** for delaying onset of stage 3 T1D in stage 2 patients. Priority review; one-year PETITE-T1D Phase 4 data. Reinforces the BSPED consensus paper picked up in PubMed (PMID 42051156). Evidence level: regulatory action (high).

2. **Phase 3 topline — PIONEER TEENS, oral semaglutide in T2D 10–17y** (Apr 23, 2026, Novo Nordisk). Superior HbA1c reduction vs placebo, well-tolerated. Filing for label expansion expected H2 2026. First oral GLP-1 RA trial in pediatrics. Evidence level: company topline (medium pending publication).

3. **FDA approval — first generic dapagliflozin tablets** (Apr 7, 2026). Earlier in the window but worth recording as it materially changes the SGLT2 access/equity picture; relevant to the Gap Analysis Tier 1 access-equity intersection above.

No verified Phase 3 readouts beyond the above; nothing detected for Vertex zimislecel, retatrutide, or Sana Bio in the last 7 days.

---

## Recommended Actions

1. **Update tracker — newly completed Phase 3 result:** Add `NCT05649137` (semaglutide, excess weight + T2D, Novo Nordisk; results posted 2026-04-27) to `Diabetes_Research_Tracker.xlsx`.
2. **Update tracker — orforglipron program:** Note `NCT06993792` status change to ACTIVE_NOT_RECRUITING — Master Protocol moving toward readout.
3. **Update tracker — Tzield label expansion (Apr 22):** Cross-link the FDA approval with PMID 42051156 (BSPED consensus) and `NCT07088068` (ongoing 1–25y Phase 3) for a single teplizumab evidence package.
4. **Re-run gap analysis:** `literature_gap_data.json` is 10 days old. While still within the 14d threshold, the Nature quintuple-agonist paper and the Nature Metabolism epigenetics paper would shift several intersection counts. Run `python project1_literature_gap_analysis.py` ahead of any synthesis brief.
5. **Cross-domain paper review queue (priority):**
   - PMID **42056522** (Nature, GLP-1R/GIPR/PPAR quintuple agonism) — read full text; relevant to T2D GLP-1 New and GLP-1 Pharmacogenomics dashboards.
   - PMID **42050914** + PMID **42051156** + PMID **42023429** — combine into a single T1D immunotherapy + gene therapy synthesis update; Tier 1.
   - PMID **42032109** (Nat Metab α/β cell methylation) — flag for Epigenetics + Gene Therapy intersection write-up.
6. **De-tag check:** PMID **42046753** (active breaks in T1D) appears tagged "T1D Immunotherapy" in error. Adjust the keyword filter in `baseline_pubmed_alerts.py` if the misclassification is reproducible.
7. **No file refresh required today:** All baseline scripts ran on schedule and outputs are current. Standing recommendation: re-run `python project1_literature_gap_analysis.py` after 5 May to incorporate the week's new cross-domain papers.

---

## Validation Notes (per RESEARCH_DOCTRINE.md)

| Claim | Evidence Level | Source |
|-------|---------------|--------|
| Trial counts and statuses | GOLD (machine-extracted from ClinicalTrials.gov v2 API) | `clinical_trials_latest.json` 2026-04-30 |
| PubMed paper listings | GOLD (E-utilities, deduplicated) | `pubmed_recent_latest.json` 2026-04-30 |
| Cross-domain tagging | BRONZE (keyword overlap; one false-positive flagged above) | `pubmed_recent_latest.json` |
| Gap scores | BRONZE (single bibliometric source) | `literature_gap_report.md` |
| FDA Tzield expansion + PIONEER TEENS topline + generic dapagliflozin | SILVER (regulatory/company sources) | Web search 2026-04-30 |

*This report was generated by the diabetes-hub-monitor scheduled task. No files were modified outside `Analysis/Results/`. Report follows the change-only structure in `SKILL.md`.*
